Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer.

We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16α-[F]fluoro-17β-estradiol ([F]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F]-FDG PET because of physiological [F]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F]-FES PET imaging. [F]-FES PET could be used to prove the presence of ER-positive metastases in the brain.